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Background: The prognosis of patients with advanced biliary tract cancer (BTC) is extremely poor and only a few
standard treatments are available for this condition. We performed a phase I trial to investigate the safety, immune
response and anti-tumor effect of vaccination with three peptides derived from cancer-testis antigens.
Methods: This study was conducted as a phase I trial. Nine patients with advanced BTC who had unresectable
tumors and were refractory to standard chemotherapy were enrolled. Three HLA-A*2402 restricted epitope
peptides-cell division cycle associated 1 (CDCA1), cadherin 3 (CDH3) and kinesin family member 20A (KIF20A)-were
administered subcutaneously, and the adverse events and immune response were assessed. The clinical effects
observed were the tumor response, progression-free survival (PFS) and overall survival (OS).
Results: The three-peptide vaccination was well-tolerated up to a dose of 3 mg per peptide (9 mg total). No grade
3 or 4 adverse events were observed after vaccination. Peptide-specific T cell immune responses were observed in
all patients and stable disease was observed in 5 of 9 patients. The median PFS and OS were 3.4 and 9.7 months.
The Grade 2 injection site reaction and continuous vaccination after PD judgment appeared to be prognostic of OS.
Conclusions: Multiple-peptide vaccination was well tolerated and induced peptide-specific T-cell responses.
Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials
Registry (UMIN-CTR000003229).
Keywords: Cancer vaccine, Peptide vaccine, Immunotherapy, Biliary tract cancerBackground
Biliary tract cancer (BTC) is not a common disease world-
wide, but is prevalent in East Asia and Latin America. The
occurrence rate is gradually increasing and there is a high
mortality rate because most cases of BTC are not diag-
nosed until advanced and inoperable. At this time, very
few standard treatments have been established for BTC
[1,2], and thus development of new treatment modalities is
urgently needed. Recently, cancer vaccines using synthetic
peptides have been undergoing development throughout
the world, and some of them have already been shown to
be safe and effective [3-12]. We have previously reported
that cancer peptide vaccines are capable of inducing* Correspondence: aruga.atsushi@twmu.ac.jp
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unless otherwise stated.antigen-specific cytotoxic T cells in vivo and providing
some clinical benefit to some patients with advanced bil-
iary tract cancer [13]. In this study, we selected three
cancer-testis antigens that were identified by using cDNA
microarray technology coupled with laser microdissection
and were overexpressed in nearly 100% of BTC. We then
performed a phase I study to assess the safety and antigen-
specific immune response of a three-peptide vaccination
using the selected antigens in patients with advanced
biliary tract cancer. Patients were vaccinated on a con-
tinuous basis over the long-term even if their disease
had progressed. We assessed the safety of the vaccin-
ation by CTCAE v3.0 as a primary endpoint and the
antigen-specific immune response and clinical effects as
secondary endpoints.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patient eligibility
Patients with unresectable BTC (intrahepatic bile duct
cancer, extrahepatic bile duct cancer and gallbladder can-
cer) who were refractory to standard chemotherapy were
eligible for this study. All patients were required to have
an HLA-A type of A*2402. Additional inclusion criteria
consisted of age between 20 and 80 years, no severe organ
function impairment, white blood cell count between
2000 and 10000/mm3, hemoglobin > 8 mg/dL, platelet
count > 100,000/mm3, AST and ALT < 100 IU/L, and total
bilirubin < 2 mg/dl. Performance status measured by the
ECOG scale was 0 to 2. It was required that there be an at
least 4-week interval since the last chemotherapy. The ex-
clusion criteria consisted of pregnancy, serious infections,
severe underlying disease, severe allergic disease and a
judgment of unsuitability by the principal investigator.
Study design and endpoints
This study was conducted as a phase I trial. Patients
who received standard chemotherapy under a diagnosis
of inoperable BTC between June 2009 and May 2010
were invited to participate after providing their informed
consent. The HLA-A genotypes of these patients were
examined, and the 9 patients with an HLA-A type of
A*2402 were enrolled. Three peptides were used for the
vaccine, CDCA1 (VYGIRLEHF) [14], CDH3 (DYLNEW
GSRF) [15] and KIF-20A (KVYLRVRPLL) [16]. These pep-
tides were chosen from among the antigens identified by
using cDNA microarray technology coupled with laser mi-
crodissection and were the most overexpressed in BTCs.
The purity (>97%) of the peptides was determined by ana-
lytical high-performance liquid chromatography (HPLC)
and mass spectrometry analysis. The endotoxin levels and
bioburden of these peptides were tested and determined to
be within acceptable levels based on the GMP grade for the
vaccines (PolyPeptide or NeoMPS Inc., San Diego, CA,
USA). These peptides were mixed with incomplete Freund's
adjuvant (IFA; Montanide ISA51, SEPPIC),which has been
used in many clinical studies, and were injected sub-
cutaneously into the inguinal or the axicilla site. Each of
the three peptides at doses of 1 mg, 2 mg or 3 mg was
injected subcutaneously into three patients once a week
until the 8th vaccination and every two weeks after the
9th vaccination as a monotherapy as long as possible
even if the patient was judged to exhibit disease pro-
gression. The primary endpoint in this study was the as-
sessment of toxicities caused by the vaccination based on
the Common Terminology Criteria for Adverse Events ver-
sion 3.0 (CTCAE v.3.0). The secondary endpoints were as-
sessment of the immunological response, tumor response,
progression-free survival (PFS) and overall survival (OS)
from the 1st dose given. For the image analysis, CT scan
or ultrasound was performed during the pre-vaccinationperiod and at every 4th vaccination. This study was ap-
proved by the institutional review board at Tokyo Women's
Medical University and was registered with the University
Hospital Medical Information Network Clinical Trials
Registry (UMIN-CTR number, 000003229). Informed con-
sent was obtained from all the patients and the proce-
dures followed were in accordance with the Declaration
of Helsinki.
Lymphocyte preparation for immunologic monitoring
The performance of the immunologic assay at the center
laboratory was periodically standardized and validated by
Clinical Laboratory Improvements Amendments (CLIA)
and the International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuti-
cals for Human use (ICH) guidelines. PBLs were obtained
from the patients at the pre-vaccination period and after
every 4th vaccination. Peripheral blood was taken by veni-
puncture, collected in an EDTA tube and transferred to
the center laboratory within 24 hrs at room temperature.
Within 24 hrs of blood collection, PBLs were isolated with
Ficoll-Paque Plus (GE Healthcare Bio-sciences, Piscataway,
NJ) density gradient solution and were stored at -80°C in
cell stock media (Juji Field) without serum at 5 × 106 cells/
ml. After thawing, the cell viability was confirmed to be
more than 90% by trypan-blue dye.
Enzyme-linked immunospot (ELISPOT) assay
The peptide-specific CTL response was estimated by ELI
SPOT assay following in vitro sensitization. Frozen PBMCs
derived from the same patient were thawed at the same
time, and the viability was confirmed to be more than
90%. PBMCs (5 × 105/ml) were cultured with 10 μg/ml of
the respective peptide and 100 IU/mL of IL-2 (Novartis,
Emeryville, CA) at 37°C for two weeks. The peptide
was added to the culture at day 0 and day 7. Following
CD4+ cell depletion by a Dynal CD4 Positive Isolation
Kit (Invitrogen, Carlsbad, CA), an IFN-γ ELISPOT assay
was performed using a Human IFN-γ ELISpot PLUS kit
(MabTech, Nacka Strand, Sweden) according to the
manufacturer’s instructions. Briefly, HLA-A*2402-positive
B-lymphoblast TISI cells (IHWG Cell and Gene Bank,
Seattle, WA) were incubated with 20 μg/ml of vaccinated
peptides overnight, and then the residual peptide in the
media was washed out to prepare peptide-pulsed TISI cells
as the stimulation cells. Prepared CD4- cells were cultured
with peptide-pulsed TISI cells (2 × 104 cells/well) at a 1/1,
1/2, 1/4 or 1/8 mixture ratio of responder cells to stimula-
tor cells (R/S ratio) on a 96-well plate (Millipore, Bedford,
MA) at 37°C overnight. Non-peptide-pulsed TISI cells were
used as a negative control for the stimulator cells. To con-
firm IFN-γ productivity, the responder cells were stimu-
lated with PMA and ionomycin (3 μg/ml) overnight, then
applied to an IFN-γ ELISPOT assay (2.5 × 103 cells/well)
Table 1 Patient characteristics
Patients Age/Sex Tumor site* Prior therapy** Peptide
Primary Metastases (mg)
1 38/F IBD Lung, bone Ope, GEM, CBDCA, TS-1, DTX 1
2 69/M GB Liver, LN Ope, GEM, TS-1 1
3 60/F GB Liver, LN Ope, GEM, TS-1 1
4 66/F IBD Liver, lung, LN, bone Ope, GEM, TS-1 2
5 75/M IBD Lung Ope, GEM, TS-1 2
6 61/F IBD Liver, LN, peritoneum GEM, TS-1, CDDP 2
7 46/M EBD Liver, LN Ope, GEM, TS-1 3
8 76/M EBD Lung Ope, GEM, TS-1 3
9 62/F EBD Lung Ope, GEM, TS-1 3
*IBD: intrahepatic bile duct; GB: gallbladder; EBD: extrahepatic bile duct; LN: lymph node.
**Ope: operation; GEM: gemcitabine; CBDCA: carboplatin; TS-1: tegafur-gimeracil-oteracil potassium; DTX: docetaxcel; CDDP: cisplatin.
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formed in triplicate wells. The plates were analyzed by an
automated ELISPOT reader, ImmunoSPOT S4 (Cellular
Technology, Ltd., Shaker Heights, OH) and ImmunoSpot
Professional Software Version 5.0 (Cellular Technology,
Ltd.). The number of peptide-specific spots was calculated
by subtracting the number of spots in the control well from
the number of spots in each of the wells with peptide-
pulsed TISI cells. The sensitivity of our ELISPOT assay was
estimated as an approximately average level by an ELISPOT




Conventional two-color analysis was performed with FITC-
conjugated anti-human CXCR3 mAb plus PE-conjugated
anti-human CCR4 mAb (R&D Systems, Minneapolis, MN)
in order to assess the host immune condition of the type 1/
type 2 subsets.
Statistical analysis
PFS and OS rates were analyzed using the Kaplan-Meier
method. Statistical analyses of prognostic factors were
done using the log-rank test. A p-value less than 0.05 was
considered to indicate a statistically significant difference.
All statistical analyses were conducted using IBM SPSS
Statistics 21 (IBM, USA).Table 2 Summary of adverse events
Adverse events Total (%) Grade 1 (%)
Hemoglobin 5 (55.6) 3 (33.3)
WBC 2 (22.2) 0
Lymphopenia 3 (33.3) 2 (22.2)
Neutrophil 2 (22.2) 0
Platelet 3 (33.3) 3 (33.3)
Injection site reaction 9 (100) 4 (44.4)Results
Patient characteristics
Nine patients (4 males and 5 females; median age:
61.4 years; range: 38-76) whose HLA type was A*2402
were enrolled in this study (Table 1). Their primary
tumor site was the intrahepatic bile duct in 4 cases, the
extrahepatic bile duct in 3 cases, and the gallbladder in 2
cases. They had several metastases to the liver, lungs,
lymph nodes, peritoneum and bone. Previous therapies
consisted of operation, gemcitabine (GEM), cisplatin (CD
DP), tegafur-gimeracil-oteracil potassium (TS-1), carbopla-
tin (CBDCA) or docetaxcel (DTX). One patient dropped
out after the 1st follow-up study because of another disease
and 4 patients elected to stop vaccination at the time of
PD judgment. Four patients decided to continue the vac-
cination as long as possible after PD judgment.Assessment of toxicity
Toxicity was assessed by CTCAE v3.0 (Table 2). Four of
9 patients developed grade 1 injection site reaction and 5
developed grade 2 injection site reaction. Low hemoglobin,
WBC, lymphopenia, neutrophil and platelet counts were
observed before the 1st vaccination and were not worsened
throughout the vaccination term. No other adverse events
were seen throughout the peptide vaccination. Therefore,
the multiple-peptide vaccine therapy was well-tolerated up
to a dose of 3 mg for each peptide, or 9 mg total.Grade 2 (%) Grade 3 (%) Grade 4 (%)
2 (22.2) 0 0
2 (22.2) 0 0
0 1 (11.1) 0
2 (22.2) 0 0
0 0 0
5 (55.6) 0 0
Figure 1 Immunological monitoring assay of T cell response to CDCA1, CDH3 and KIF20A in patient 8. (a) IFN-γ ELISPOT assay for CDCA1,
CDH3 and KIF20A. (b) IFN-γ positive spots at several R/S ratio.
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Antigen-specific immune response was assessed by the
ELISPOT assay. In the assay, CDCA1, CDH3 and KIF20A
peptides-specific IFN-γ spots were observed in 9 of 9 pa-
tients (Figure 1). The response to every antigen in every pa-
tient was determined using our algorithm (Additional file 1:
Figure S1) is summarized in Tables 3 and 4. The number of
peptide-specific IFN-γ spots gradually increased with the
number of vaccinations (Figure 2). These immune re-
sponses were not found for all antigens or for all patients
after 8 vaccinations when the clinical assessments were
done, but they were observed after the judgment of PD
in some patients with continuous peptide vaccination.
The group receiving 3 mg of each peptide tended to
show stronger CTL induction throughout the course of
this study.Table 3 Summary of clinical outcome and immunological resp
Patients No. of vaccine Clinical response* PFS (days) OS (da
1 16 SD 212 310
2 8 PD 53 134
3 18 SD 127 205
4 19 SD 505 659
5 27 SD 225 290
6 10 SD 101 101
7 13 PD 64 164
8 24 PD 64 353
9 25 PD 57 380
*SD: stable disease; PD: progressive disease.
**ISR: injection site reaction.Clinical response
As shown in Tables 3, 5 patients had stable disease (SD)
and 4 had progressive disease (PD) as judged after the
8th vaccination. The 8 patients continued to be adminis-
tered the vaccination and 4 of them continued to receive
the vaccination for as long as possible, even if their dis-
ease developed PD. The vaccinations eventually achieved
disease stability in the patients who received the long-term
vaccination (Figure 3 shows the CT scan of patient 4),
but in the end their diseases progressed, and they had
all died within 2 years of the 1st vaccination. Their me-
dian progression-free survival (PFS) for all patients after
the first vaccination was 3.4 months (95% CI: 0-7.0) and
the 1 year PFS was 11.1% (Figure 4a). The median over-
all survival (OS) for all patients was 9.7 months (95%
CI: 1.4-18.0) and the 1 year OS was 22.2% (Figure 4b).onse
ys) After vaccine ISR** (Grade) Peptide-specific CTL
CDCA1 CDH3 KIF20A
No 2 0 1+ 1+
No 1 2+ 0 1+
No 1 1+ 2+ 1+
Yes 2 1+ 0 1+
No 2 1+ 1+ 3+
1 1+ 1+ 0
Yes 1 2+ 1+ 2+
Yes 2 3+ 3+ 3+
Yes 2 2+ 3+ 2+
Table 4 CTL response to CDCA1, CDH3 and KIF20A
Peptide dose No. Course CTL response
CDCA1 CDH3 KIF20A Positive control
1 mg 1 Pre - + - +++
Post 1 - - + +++
Post 2 - - - +++
2 Pre - - - +++
Post 1 ++ - + +++
3 Pre + - - +++
Post 1 NA* NA NA +++
Post 2 - + - +++
Post 3 + ++ - +++
Post 4 + - + +++
2 mg 4 Pre + - + +++
Post 1 - - + +++
Post 2 + - + +++
Post 3 - - - +++
5 Pre - - - +++
Post 1 - - - +++
Post 2 - - + +++
Post 3 + - +++ +++
Post 4 - - ++ +++
Post 5 + + - +++
Post 6 - - - +++
6 Pre - + - +++
Post 1 + + - +++
Post 2 + + - +++
3 mg 7 Pre NA NA NA +++
Post 1 - - - +++
Post 2 ++ + ++ +++
8 Pre - - + +++
Post 1 - + - +++
Post 2 ++ + ++ +++
Post 3 +++ +++ + +++
Post 5 +++ +++ +++ +++
9 Pre + - + +++
Post 1 ++ + + +++
Post 2 - + - +++
Post 3 - +++ + +++
Post 4 ++ - - +++
Post 6 ++ + ++ +++
*NA: not analyzed.
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The results of the univariate analysis of the prognostic
factors are described in Table 5. The patients who devel-
oped grade 2 local skin reaction at the vaccination siteshowed a median OS of 11.8 months (95% CI: 8.7-14.9).
This was better than the OS of patients with grade 1 local
skin reaction of 4.5 months (95% CI: 2.4-6.5). There was a
significant difference between these 2 groups (p = 0.003)
Figure 2 Kinetics of the peptide-specific T cell response after vaccination. Specific spots were counted as shown in Additional file 1: Figure S1
to CDCA1 (solid line), KIF20A (dotted line) and CDH3 (dashed line). The R/S ratio was 0.50.
Table 5 Prognostic factors of PFS or OS
Factors PFS OS
Sex (male/female) 0.426 0.302
Age (≧61/<61) 0.706 0.084
CRP (≧1.5/<1.5) 0.654 0.832
Hemoglobin (≧12/<12) 0.351 0.435
Lymphocyte (%) (≧27/<27) 0.145 0.132
Lymphocyte (number) (≧1500/<1500) 0.488 0.900
CDCA1 CTL spots (≧2+/<2+) 0.004 0.870
CHD3 CTL spots (≧2+/<2+) 0.235 0.611
KIF20A CTL spots (≧2+/<2+) 0.486 0.840
CXCR3 + CCR4- T cells (≧8%/<8%) 0.046 0.966
CXCR3 + CCR4- T cells (up/down) 0.007 0.604
Injection site reaction (≧Grade2/<Grade2) 0.145 0.003
Continuous vaccination after PD (Yes/No) - 0.007
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nations was also better than that of the patients who
stopped the vaccination as their disease progressed. The
OS of the patients with continuous vaccinations was
5.1 months (95% CI: 0-11.3) and that of the patients who
stopped the vaccination was 2.6 months (95% CI: 2.1-3.1).
There was a statistically significant difference between these
2 groups (p = 0.007) (Figure 4d).
Analysis of the relation between better PFS and the type
1 host immune condition
The type 1 host immune condition was analyzed based
on the ratio of the CXCR3 + CCR4- T cell population
(mean: 8.1%). The patients with a CXCR3 + CCR4- T cell
population of more than 8% showed longer PFS and the
patients whose CXCR3 + CCR4- T cell population in-
creased after the 4th vaccinations also showed longer PFS
(Table 5). Most of the patients with stable disease (SD)
showed an increase in the CXCR3 + CCR4- type 1 T cell
population (Figure 5a) and a decrease in the CXCR3-
Figure 3 Clinical response assessment in the longest-surviving patient, patient 4. CT imaging of the liver, lung and para-aortic lymph node
metastasis before vaccination (a), 6 months after 1st vaccination (b) and 12 months after 1st vaccination (c). The tumor sizes were stable across
the 505 days after 1st vaccination.
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(Figure 5b). In contrast, all the patients with progressive
disease (PD) showed a decrease in the CXCR3 +CCR4- T
cell population and an increase in the CXCR3-CCR4+ T
cell population after the 4th vaccination. Therefore, the
type 1 host immune condition was suspected to be an im-
portant factor for achieving disease stability through the
induction of peptide-specific CTLs in vivo.
Discussion
It is difficult to detect BTCs in the early stage, and this
difficulty is partly responsible for the poor prognosis of
the disease. Operation is the most effective treatment,but recurrence or metastasis occurs at a high rate following
curative operation. Other than operation, chemotherapy is
the only therapy currently available. Nevertheless, GEM
plus CDDP, which is the best choice of chemotherapy for
BTC, only yields a median overall survival of 11.7 months
and progression-free survival of 8.0 months. However, a
median overall survival of 9.7 months was realized using a
three-peptide vaccination after the failure of standard che-
motherapies, and thus this modality might have potential
for improving the OS in patients with BTC.
In this study, we selected three new peptides for BTC.
CDCA1 is a molecular linker between the kinetochore
attachment site and the tubulin subunits. CDH3 is a
Figure 4 Progression-free survival and overall survival in all enrolled patients. (a) Progression-free survival after 1st vaccination. The MST
was 3.4 months and the 1-year PFS ratio was 11.1%. (b) Overall survival after the 1st vaccination. The MST was 9.7 months and the 1-year OS ratio
was 22.2%. (c) Overall survival of the patients with Grade 2 ISR (solid line) compared to that of the patients with Grade 1 ISR (dotted line). There
was a statistically significant difference between these 2 groups (p = 0.003). (d) Overall survival of the patients receiving continuous vaccination
(solid line) compared to that of the patients who stopped the vaccination at the determination of PD (dotted line). There was a statistically significant
difference between these 2 groups (p = 0.007).
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transduction for cell growth and differentiation. KIF20A
is a conserved motor domain that binds to microtubules.
We previously reported on other combinations of peptides
for vaccination in patients with BTC. We found that
DEPDC1 and LY6K strongly induced antigen-specific
CTLs after the 4th vaccination. In contrast, IMP3 and
TTK induced CTLs only weakly and late after the vaccin-
ation. The three-peptide vaccination in this study also
showed a delayed induction of peptide-specific CTLs. We
speculate that this might have been due to differences in
the abilities of the peptides to induce a host immuneresponse. In these cases, most of the patients were judged
as having PD before the strong CTLs were induced
in vivo. The protocol of this study permitted the continu-
ation of vaccination after the diagnosis of PD, and the pa-
tients who continued vaccination after the start of PD had
a strong CTL induction and showed better prognosis
compared with other patients who stopped the vaccin-
ation at the time of PD judgment. Therapeutic cancer vac-
cination seems to show a delayed clinical effect [17] and
the early discontinuance of vaccination might cause a mis-
appraisal of the true capacity of the cancer vaccine. There-
fore, there may be need of a further clinical study in which
Figure 5 Kinetics of type 1 T cell population and type 2 T cell population after vaccination. (a) The population of CXCR3 + CCR4- type 1 T cells
increased in most of the patients with stable disease (SD) (solid line) and decreased all the patients with progressive disease (PD) (dashed line) after 4
vaccinations. (b) The population of CXCR3-CCR4+ type 2 T cells was decreased in most of the patients with SD (solid line) and increased in all the
patients with PD (dashed line) after 4 vaccinations.
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diagnosis of PD in the early stage of study, because the in-
duction of CTLs was often fairly slow.
Several phase III randomized studies of cancer vac-
cines have been performed [18], but very few of them
were successful [19]. The clinical efficacy of cancer vac-
cines is currently limited because of the immune check-
point. Anti-CTLA-4 mAb (ipilimimab) [20], anti-PD-1
[21,22] and PD-L1 [23] have shown promising results in
some clinical studies. Although the blockage of the immune
checkpoint itself is an effective therapy, it also seems to be
necessary to administer the cancer antigen-specific CTLs.
Cancer peptide vaccines could induce antigen-specific
CTLs in vivo, so the combination of a cancer vaccine and
immune checkpoint blockade would be a more successful
anti-cancer strategy in the future. Another approach might
be to improve the immune condition of the host. A proper
number of lymphocytes, especially type 1 T cells, seems to
be needed to acquire a good immune response, which in
turn has been associated with a better prognosis [24,25]. In
order to ensure the success of clinical trials, a new classifi-
cation method or biomarker is needed to stratify patients
according to their immune condition [26-30].
In this report, a new three-peptide vaccine was shown
to be safe and to elicit an effective immune response in
patients with advanced biliary tract cancer. No patients
exhibited a CR or PR, but it was suggested that the OS
could be extended by continuous administration of this
vaccination. In order to establish this immunotherapy as
the standard therapy for biliary tract cancer, it will benecessary to assess the survival improvement in a phase
II/III randomized trial with an appropriate number of
subjects. We have reported 4 peptides previously and 3
new peptides in this study. All 7 of these peptides could
be used simultaneously for patients with advanced BTC,
or one or more of them could be selected for patients in
an adjuvant setting after operation and examination of
the antigen expression profile in their tumor cells.Conclusions
We have shown that a cancer peptide vaccine therapy
using a mixture of three peptides was well tolerated and
could induce peptide-specific CTLs in patients with ad-
vanced BTC. The peptide vaccine was found to have a
sufficient effect on survival to merit further evaluation in
clinical trials.Additional file
Additional file 1: Algorithm of the assessment of CTL response to
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